@article{APS10445,
author = {Tian-bang Wu and Qiu-ping Xiang and Chao Wang and Chun Wu and Cheng Zhang and Mao-feng Zhang and Zhao-xuan Liu and Yan Zhang and Lin-jiu Xiao and Yong Xu},
title = {Y06014 is a selective BET inhibitor for the treatment of prostate cancer},
journal = {Acta Pharmacologica Sinica},
volume = {42},
number = {12},
year = {2021},
keywords = {},
abstract = {Bromodomain and extra-terminal proteins (BETs) are potential targets for the therapeutic treatment of prostate cancer (PC). Herein, we report the design, the synthesis, and a structure−activity relationship study of 6-(3,5-dimethylisoxazol-4-yl)benzo[cd]indol-2 (1H)-one derivative as novel selective BET inhibitors. One representative compound, 19 (Y06014), bound to BRD4(1) in the low micromolar range and demonstrated high selectivity for BRD4(1) over other non-BET bromodomain-containing proteins. This molecule also potently inhibited cell growth, colony formation, and mRNA expression of AR-regulated genes in PC cell lines. Y06014 also shows stronger activity than the second-generation antiandrogen enzalutamide. Y06014 may serve as a new small molecule probe for further validation of BET as a molecular target for PC drug development.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/10445}
}